louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00403975: Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease
Official title: A Multi-Center, Parallel Group, Double-Masked, Randomized, Placebo-Controlled Study of Multiple Ocular Instillations of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dry Eye Disease
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2006-11-27
Enrollment: 640
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to assess the effectiveness and safety of 2% diquafosol tetrasodium ophthalmic solution versus placebo following 6 weeks of treatment in subjects with mild to moderate dry eye disease.


Eligibility criteria: Inclusion Criteria:

* best corrected visual acuity in both eyes of at least +0.7
* six-month documented history of dry eye disease
* as least mild severity in 1 of the 5 dry eye symptoms
* corneal fluorescein staining of greater than or equal to 3 and less than or equal to 6 (out of 15)

Exclusion Criteria:

* permanent conjunctival goblet cell loss or scarring conditions
* ongoing contact lens wear
* current topical ophthalmic medication use

Primary outcomes:
measure: Change in dry eye testing measures
Secondary outcomes:
measure: Change in dry eye testing measures and symptoms
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04372875: Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: a Pragmatic Trial
Official title: Leveraging Health Information Technology to Reduce Health Disparities in Adolescent Health Outcomes: a Patient-Centered Approach
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sexually Transmitted Diseases
Lead sponsor: Children's National Research Institute
Sponsor class: OTHER
First posted: 2020-05-04
Enrollment: 37500
Sex: ALL
Minimum age (years): 15
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: SCREENING

Brief summary: We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs. at risk) and race/ethnicity.


Eligibility criteria: Inclusion Criteria:

* Adolescents aged 15-21 years seeking care in the emergency department

Exclusion Criteria:

* Patients will be excluded if unable to understand English, are critically ill, cognitively impaired, or otherwise unable to provide consent for completion of the sexual health survey (SHS) and STI screening.

Primary outcomes:
measure: Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (GC) detection rates
timeFrame: 3-7 days after emergency department (ED) visit
Secondary outcomes:
measure: STI rates by race/ethnicity
timeFrame: 3-7 days after ED visit
Other outcomes:
Locations:
city: Washington
country: United States
facility: Children's National Hospital
state: District of Columbia
Study officials:
References:
Clinical trial NCT03419975: A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Official title: A Multi-center, Randomized,Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in Primary Open Angle Glaucoma or Ocular Hypertension Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Open-angle Glaucoma
Ocular Hypertension
Lead sponsor: Taejoon Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-02-05
Enrollment: 146
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control administration groups.


Eligibility criteria: * Inclusion Criteria:

  * Male or female, age 19 or over
  * Written informed consent to participate in the trial
* Exclusion Criteria:

  * Any other Galucoma except POAG(ex, Closed anterior chamber angle, angle-closure glaucoma)
  * Any laser or ocular surgery within 3months prior screening
  * Use of contact lenses
  * Known reactive airways disease
  * Any condition limiting patient's ability to participate in the trial

Primary outcomes:
measure: Change From Baseline in diurnal IOP at Week 12
timeFrame: Baseline and Week 12
Secondary outcomes:
measure: Change From Baseline in diurnal IOP at Week 8
timeFrame: Baseline and Week 8
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Chan Yun, Kim
Study officials:
References:
Clinical trial NCT05971875: RCT on 3 Types of Hysterectomy
Official title: A Multinational Randomized Controlled Trial Including Two Identical Sub Studies Comparing Vaginal Versus vNOTES (Vaginal Natural Orifice Transluminal Surgery) Hysterectomy or Laparoscopic Versus vNOTES Hysterectomy.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Minimally Invasive Surgery
Lead sponsor: Imelda Hospital, Bonheiden
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized controlled trial comparing the vaginal, vNOTES ( vaginal natural orifice transluminal surgery) or laparoscopic approach for hysterectomy in women with benign gynaecological disease

Detailed description: Multi-center pragmatic non-blinded RCT including 1000 women 18-75 years in need of hysterectomy for benign disease; comparing VH vs vNOTES or LH vs vNOTES.

Eligibility criteria: Inclusion Criteria:

• Women aged 18 to 75 years regardless of parity with benign indication for hysterectomy

Exclusion Criteria:

* Women with a stage II+ prolapse in need of a hysterectomy as part of vaginal prolapse repair
* hysterectomy due to suspected endometriosis
* subtotal hysterectomy
* history of rectal surgery
* suspected malignancy
* suspected obliteration of the pouch of Douglas following severe PID or other causes
* active lower genital tract infection
* pregnancy
* failure to provide written informed consent prior to surgery
* requirement of in-patient care due to other co-morbidities

Primary outcomes:
measure: proportion of women leaving the hospital within 12 hours after surgery complications.
timeFrame: 12 hours
Secondary outcomes:
measure: Hospitalization time
timeFrame: 6 weeks
measure: conversion rates
timeFrame: 12 hours
measure: duration of the surgical procedure
timeFrame: 12 hours
measure: Intraoperative complications.
timeFrame: 12 hours
measure: postoperative complications,
timeFrame: 6 weeks
measure: re-admission requiring hospitalization
timeFrame: 6 weeks
measure: Patient Reported Outcome Measures.
timeFrame: 3 months postop
Other outcomes:
Locations:
city: Zadar
country: Croatia
facility: Dept of Obstetrics and Gynecology
city: Helsingborg
country: Sweden
facility: Dept of Obstetrics and Gynecology
Study officials:
affiliation: Imeldaziekenhuis
name: JAn Baekelandt
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00647075: Yunzhi as Dietary Supplement in Breast Cancer
Official title: A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Breast Cancer
Keywords: Breast cancer
undergoing
adjuvant/neoadjuvant chemotherapy
symptomatic therapy
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2008-03-31
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the effects of a dietary supplement, the traditional Asian mushroom Yunzhi, as adjuvant in the treatment of patients with breast cancer.


Eligibility criteria: Inclusion Criteria:

1. Women with diagnosis of breast cancer
2. Undergoing adjuvant/neoadjuvant chemotherapy with either FEC, FAC, TAC, or EC + docetaxel combinations.
3. ≥ 18 years of age
4. Performance status: 0-2
5. Ability to provide written informed consent

Exclusion Criteria:

1. Any prior history of yunzhi use
2. Use of other herbal remedies during the study duration
3. Significant cardiac, pulmonary, renal, hepatic, gastrointestinal, CNS, psychiatric disease or illicit substance use/abuse that in the opinion of the investigator would make the participant a poor candidate for study participation
4. Pregnancy (for women of childbearing potential, a negative pregnancy test, urine or serum, is required within 14 days prior to randomization)
5. Systemic use of progestins, androgens or other steroids (dexamethasone is allowed if used as antiemetic therapy)

Primary outcomes:
measure: Mean change in signs and symptoms from baseline measured by Visual Analogue Scale (VAS)
timeFrame: 6 months
Secondary outcomes:
measure: Treatment adherence Clinical and laboratory (including RBC, WBC and platelets) adverse events Adherence to chemotherapy schedule EPO and blood transfusion needs
timeFrame: 6 months
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Hospital Parc Tauli
state: Barcelona
city: Barcelona
country: Spain
facility: Hospital Clinic
Study officials:
affiliation: Hospital Clinic
name: Pere Gascon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01835275: Audio-enhanced Analgesia in Healthy Subjects
Official title: Audio-enhanced Analgesia in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2013-04-18
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether enhanced audio methods can be used to improve analgesia for experimental pain in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* 18-50 years old
* Healthy

Exclusion Criteria:

* Current diagnoses of psychiatric or neurological disorders or chronic pain
* BDI-II score greater than 13
* current or previous ear/nose/throat or hearing issues
* prior participation in pain studies
* previous advanced music training

Primary outcomes:
measure: Pain Intensity and Unpleasantness
timeFrame: 1.5 hour testing session
Secondary outcomes:
Other outcomes:
Locations:
city: Charlestown
country: United States
facility: Department of Psychiatry, Mass General Hospital
state: Massachusetts
Study officials:
References:
citation: Hsieh C, Kong J, Kirsch I, Edwards RR, Jensen KB, Kaptchuk TJ, Gollub RL. Well-loved music robustly relieves pain: a randomized, controlled trial. PLoS One. 2014 Sep 11;9(9):e107390. doi: 10.1371/journal.pone.0107390. eCollection 2014.
Clinical trial NCT00307775: Vaginal Estrogen for the Treatment of Faecal Incontinence in Women
Official title: A Pilot Study to Examine the Efficacy of Vaginally Administered Oestradiol in the Treatment of Faecal Incontinence in Post Menopausal Women
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Fecal Incontinence
Keywords: oestradiol, faecal incontinence, post menopausal
post menopausal women with faecal incontinence
Lead sponsor: London North West Healthcare NHS Trust
Sponsor class: OTHER
First posted: 2006-03-28
Enrollment: 43
Sex: FEMALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will address the following questions:

* Does the use of oestrogen inserted vaginally with an applicator, help with the symptoms of faecal (bowel) incontinence in women who are past the age of menopause?
* Do women find it easy to use?
* Is the treatment safe for the womb lining?
* Is there any systemic absorption of the treatment?

Detailed description: Faecal incontinence affects about 5% of women, the most common cause is often cited by women as obstetric trauma. However in clinical practice many women report that their symptoms of faecal incontinence begin around the same time as menopause. A community survey examining the prevalence of faecal incontinence in menopausal women is in progress. If a correlation is found between the onset of menopause and the development of faecal incontinence, further investigation of effective treatment will be indicated.

The investigators want to investigate whether vaginally administered oestradiol can alleviate or improve symptoms in women who have faecal incontinence after the menopause. This is a pilot study.

Eligibility criteria: Inclusion Criteria:

* Post menopausal women with faecal incontinence

Exclusion Criteria:

* No hormone replacement therapy (HRT) for at least 8 weeks prior to screening
* Diabetes mellitus
* Neurological disorder
* Terminal illness
* Current treatment for breast cancer
* Unable to give informed consent

Primary outcomes:
measure: Improvement of symptoms and quality of life (QoL) as measured by QoL questionnaires and physiological assessment
Secondary outcomes:
measure: Acceptance of treatment mode delivery, through questionnaire
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: North West London Hospitals NHS Trust
Study officials:
affiliation: London North West Healthcare NHS Trust
name: Kathy Abernethy, RN ENB
role: PRINCIPAL_INVESTIGATOR
affiliation: London North West Healthcare NHS Trust
name: Joan Pitkin, MB BS BSc FRCS FRCOG
role: STUDY_CHAIR
References:
Clinical trial NCT02961075: Impact of Local Anesthesia on Postbronchoscopy Fever: a Randomised Controlled Study
Official title: Impact of Local Anesthesia on Postbronchoscopy Fever: a Randomised Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Complications
Lead sponsor: The Second Affiliated Hospital of Dalian Medical University
Sponsor class: OTHER
First posted: 2016-11-10
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Impact of Local Anesthesia on Postbronchoscopy Fever: a Randomised Controlled Study

Detailed description: Fiberoptic bronchoscopy (FOB) is the essential procedures for diagnosis and treatment of respiratory diseases。 Fever following FOB has been frequently reported. Fever is usually caused by patient discomfort and delay recovery from illness, or even worse. The reported frequency of this complication ranges from 1 to 20%. According to previous reports, postbronchoscopy fever is associated with advanced age, the presence of abnormal bronchoscopic findings,documented endobronchial obstruction, bronchoscopic intervention for malignancy, BAL, bronchial brushing, endotoxin contamination during bronchoscopy, instillation of topical anesthetic through the bronchoscope, abnormal differential cell counts in the BAL fluid (BALF), bacterial growth in the BALF culture,and the severity of bleeding. At present, guidelines recommend sedation and analgesia combined with airway surface anesthesia for Fiberoptic bronchoscopy. laryngeal spray and cricothyroid anesthesia often used in clinical.Cricothyroid local anesthesia has a good effect, but it is an invasive operation, this is risk factors for fever after bronchoscopy.Therefore, to compare fever in the two kinds of airway anesthesia on Bronchoscopy . So as to provide the local anesthesia method with little influence on the patient.

Eligibility criteria: Inclusion Criteria:

* ASA I-III

Exclusion Criteria:

* use of immunosuppressive agents or corticosteroids
* body temperature 37.3°C during the 24 h prior to FOB,intubation or mechanical ventilation
* therapeutic bronchoscopy (foreign body removal, bronchial toilet, or stenting), discharge within 24 h of FOB
* surgical or diagnostic procedures within 24 h of FOB.

Primary outcomes:
measure: Fever
timeFrame: 48 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Dalian
country: China
facility: The Second Hospital of Dalian Medical University
state: Liaoning
Study officials:
affiliation: 0866-17709873399
name: Xiao z yang, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03682575: Work of Breathing in Premature Infants at Discharge
Official title: Work of Breathing and Oxygen Saturation Stability in Premature Infants With History of Respiratory Insufficiency Prior to Discharge
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bronchopulmonary Dysplasia
Very Low Birth Weight Infant
Prematurity
Lead sponsor: Christiana Care Health Services
Sponsor class: OTHER
First posted: 2018-09-24
Enrollment: 78
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Preterm infants born greater than 26 weeks gestation, weighing less than 1500 grams at birth. Work of breathing indices will be compared between the group of babies who were diagnosed with BPD and the group that was not diagnosed with BPD.

Brief summary: The purpose of this study is to compare how premature infants who required oxygen for at least 28 days during their time in the NICU (Neonatal Intensive Care Unit) breathe at discharge compared to premature infants who did not require oxygen for at least 28 days during their time in the NICU.

Detailed description: Work of breathing tests will be performed on premature infants who required oxygen for at least 28 days during their time in NICU. These same work of breathing tests will be performed in another group of premature infants who did not require oxygen for at least 28 days during their time in the NICU. The two groups will be compared.

Eligibility criteria: Inclusion Criteria:

* Infants born at greater than 26 weeks gestation, weighing less than 1500 grams at birth.
* Infants with diagnosis of BPD and without diagnosis of BPD

Exclusion Criteria:

* Infants with skeletal, neuromuscular, or abdominal surgical disorders that affect the accuracy of work of breathing measurements will be excluded.

Primary outcomes:
measure: Work of breathing indices
timeFrame: 25 minutes
Secondary outcomes:
measure: Intermittent Hypoxia
timeFrame: 25 minutes
Other outcomes:
Locations:
city: Newark
country: United States
facility: Christiana Care Health Services, Inc
state: Delaware
Study officials:
affiliation: ChristianaCare
name: Kelley Z Kovatis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02149875: Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
Official title: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Cerebral Stroke Within 12 Hours for the First Time
Keywords: Acute ischemic stroke
Dl-3-n-butylphthalide
Cerebrolysin
Lead sponsor: Shanghai 6th People's Hospital
Sponsor class: OTHER
First posted: 2014-05-29
Enrollment: 84
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.


Eligibility criteria: Inclusion Criteria:

* Acute ischemic stroke within 12 hours for the first time before entry into the study
* National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25

Exclusion Criteria:

* with lacunar infarction
* with cerebral hemorrhagic infarction
* with epilepsy or epileptic persons
* with history of neurological diseases
* with myocardial infarction,
* with renal and hepatic abnormalities
* with metabolic diseases
* with contraindications to antiplatelet treatments

Primary outcomes:
measure: National Institutes of Health Stroke Scale Score
timeFrame: At 11-day and 21-day after therapy
Secondary outcomes:
measure: Barthel Index Score
timeFrame: At 11-day and 21-day after therapy
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Sixth People's Hospital
Study officials:
affiliation: Shanghai 6th People's Hospital
name: Lixia Xue, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
citation: Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H. Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med. 2016 May;11(5):2015-2020. doi: 10.3892/etm.2016.3139. Epub 2016 Mar 10.
Clinical trial NCT02858375: Long-Term Assessment of Quality of Life and Effectiveness of Onabotulinumtoxina Injections in Provoked Vestibulodynia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vestibulodynia
Keywords: quality of life
botulinum toxin
provoked vulvodynia
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2016-08-08
Enrollment: 21
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from provoked vestibulodynia, monitored in the Dermatology Department of the University Hospital of Besançon

Brief summary: The study aims to assess and compare the pain in women suffering from provoked vestibulodynia, before treatment with botulinum injections, 3 months after treatment and 18 months after treatment.


Eligibility criteria: Inclusion Criteria:

* Vestibulodynia rated B2 according to 2003 International Society for the Study of Vulvovaginal Disease (ISSVD) classification
* Patients previously treated no later than18 months ago for provoked vestibulodynia with botulinum toxin injections, in the University Hospital of Besançon.

Exclusion Criteria:

* Major psychologic disorders.

Primary outcomes:
measure: Long-term pain improvement after botulinum toxin injections
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU Besançon
Study officials:
affiliation: CHU Besançon
name: Fabien Pelletier, MD
role: PRINCIPAL_INVESTIGATOR
References: